Device Trial Radar · NCT07950163
Paired Associative Stimulation of the Motor Cortex and the Dorsal Roots of the Cervical Spine for the Recovery of Arm and Hand Function in Chronic Middle Cerebral Artery Stroke. ASCLEPIUS Safety Evaluation Pilot Study
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Dec 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- Juan Antonio Barcia AlbacarAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Boston Scientific Corporation
- First posted
- Nov 20, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 84 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this pilot clinical trial is to learn whether paired associative stimulation (PAS) of the primary motor cortex and the cervical spinal dorsal roots, delivered through implanted epidural electrodes and combined with neurorehabilitation, is safe in adults with chronic paresis or paralysis of the arm and hand after a stroke in the territory of the middle cerebral artery. The main question it aims to answer is: \* What adverse events occur during 12 months of follow-up with this treatment? Secondary questions are whether the stimulation is feasible (whether pairing the corresponding electrode contacts of the motor cortex and the cervical spinal cord increases the motor response to stimulation) and whether it shows preliminary signs of efficacy on upper limb motor function, quality of life and caregiver burden. Researchers will compare PAS plus rehabilitation with sham stimulation plus rehabilitation during a two-month double-blind phase. Participants will: * Have epidural electrodes surgically implanted over the primary motor cortex and the cervical spinal cord, connected to an implanted pulse generator * Receive PAS or sham stimulation together with rehabilitation sessions for two months * If assigned to sham stimulation, receive open-label PAS plus rehabilitation for a further two months * Attend follow-up visits for 12 months
Conditions
- Stroke
- Infarction, Middle Cerebral Artery
- Hemiparesis
- Upper Extremity Paresis
Interventions
Epidural paired associative stimulation of the motor cortex and cervical dorsal rootsDevice
Paired associative stimulation (PAS) delivered through an implanted 32-contact pulse generator (WaveWriter Alpha, Boston Scientific) connected to an epidural lead over the primary motor cortex (Artisan MRI Surgical Lead) and two epidural leads over the cervical spinal cord, C3 to T1, placed laterally towards the dorsal roots of the affected side (Linear Lead). Cortical and cervical contacts that evoke responses in the same muscle group are paired, with an inter-stimulus delay derived from the EMG response latencies of each contact. Stimulus intensity is set immediately below the threshold for a motor response. Stimulation is applied during rehabilitation sessions and adjusted weekly for two months. The devices are CE-marked and used outside their intended purpose.
Sham epidural stimulationDevice
Same implanted system as in the experimental arm. The pulse generator is programmed with settings that are not effective for inducing paired associative stimulation: stimulation of a single contact of the spinal lead with settings that produce paresthesia but no motor response. Sham stimulation is applied during rehabilitation sessions and reviewed weekly for two months, with the same visit schedule as the experimental arm.
NeurorehabilitationOther
Multidisciplinary neurorehabilitation program for the affected upper limb combining physiotherapy and occupational therapy, delivered two or three days per week on alternate days according to clinical status and tolerance, during the stimulation phases. The program is identical in both arms and is delivered by rehabilitation staff blinded to group allocation during Phase I.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative incidence of adverse eventsTime frame: From surgery to 12 months after hospital discharge
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital Clínico San Carlos
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.